BHC's Quality Score rose 1 point on Tue, Nov 10, to 8. Trading was quieter than usual (2 chart checks started).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 31% from Oct 27 to Nov 10.
| Since its Dec 2021 high | Down 70% |
| Latest filing | 10-Q, Oct 29 |
After its last 4 reports it closed +13.9% on average, higher 3 of 4 times.
Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
BHC is #24 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 24 |
Net income over four quarters: BHC -$841M, PBH $155M, AMRX $133M, PRGO -$1.77B.
Expected to report Wed Feb 17, after the close (in 99 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase in organic 1 revenue was primarily driven by double-digit growth in Dermatology.”
BHC's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Sales grew 5% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1.1% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | +10.7% | +28.8% | +20.5% |
| Jul 29, 2026 | +6.2% | +28.9% | +34.4% |
| Apr 29, 2026 | +4.7% | +2.3% | +1.1% |
| Feb 18, 2026 | -7.8% | -4.2% | -1.3% |
Sales grew in five of the last seven years, to $10B in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 66.4, MACD above signal, above both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
“Competitive Landscape for Products and Products in Development The pharmaceutical and medical device industries are highly competitive.”
BHC scores 8 today, which Breakaway calls Average. It is #24 of 90 in Pharma by Quality Score, with 6 of 14 chart checks firing. Up 31% from Oct 27 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BHC scores 8 today, which Breakaway calls Average (6 to 10). That is #24 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BHC's 8.
Expected to report Wed Feb 17, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. BHC closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.